Skip to main content
European Commission logo print header

Ration design and standardized evaluation of novel genetic vaccines.

Cel

Recombinant viral vectors and virus-like particles are considered the most promising vehicles to deliver antigens in prophylactic and therapeutic vaccines against infectious diseases and cancer. Several potential vaccine designs exist but their cost-effective development cruelly lacks a standardised evaluation system. On these grounds, COMPUVAC is devoted to (i) rational development of a novel platform of genetic vaccines and (ii) standardisation of vaccine evaluation. COMPUVAC assembles a platform of viral vectors and virus-like particles that are among today's most promising vaccine candidates and that are backed up by the consortium's complementary expertise and intellectual property, including SMEs focusing on vaccine development. COMPUVAC recognises the lack of uniform means for side-by-side qualitative and quantitative vaccine evaluation and will thus standardise the evaluation of vaccine efficacy and safety by using "gold standard" tools, molecular and cellular methods in virology and immunology, and algorithms based on genomic and proteomic information. "Gold standard" algorithms for intelligent interpretation of vaccine efficacy and safety will be built into COMPUVAC's interactive Genetic Vaccine Decision Support System, which should generate (i) vector classification according to induced immune response quality, accounting for gender and age, (ii) vector combination counsel for prime-boost immunisations, and (iii) vector safety profile according to genomic analysis. The knowledge assembled from these studies will be applied to the development of vaccines against Hepatitis C Virus. As end products, our vector platform and "gold standard" tools, methods and algorithms will be available to the scientific and industrial communities as a toolbox and interactive database which standardised nature should contribute to cost-effective development of novel vaccines with validated efficacy and safety profile.

Słowa kluczowe

Zaproszenie do składania wniosków

FP6-2003-LIFESCIHEALTH-I
Zobacz inne projekty w ramach tego zaproszenia

System finansowania

IP - Integrated Project

Koordynator

CENTRE NATIONAL DE LE RECHERCHE SCIENTIFIQUE
Wkład UE
Brak danych
Adres
3 rue Michelange
PARIS
Francja

Zobacz na mapie

Linki
Koszt całkowity
Brak danych

Uczestnicy (18)